TY - JOUR
T1 - Synthesis, X-ray structure, and anti-leukemic activity of oxovanadium(IV) complexes
AU - Dong, Yanhong
AU - Narla, Rama Krishna
AU - Sudbeck, Elise
AU - Uckun, Fatih M.
PY - 2000/3/31
Y1 - 2000/3/31
N2 - In a systematic effort to identify and develop effective anticancer agents, four oxovanadium(IV) complexes with 1,10-phenanthroline (Phen) or 4,7-dimethyl-1,10-phenanthroline (Me2-Phen) as ligand(s) were synthesized and characterized. Among the four oxovanadium(IV) complexes synthesized, the crystal structure of the bis(phenanthroline)oxovanadium(IV) complex bis(1,10-phenanthroline)sulfatooxovanadium(IV) ([VO(SO4)(Phen)2], compound 1) has been determined. Compound 1 crystallized in the space group P21/n with unit cell parameters a=14.2125 (17) A, b=10.8628 (13) A, c=20.143 (2) A, α=90°, β=102.569 (2)°, γ=90°, V=3035.3 (6) A3, and Z=4. The refinement of compound 1 by full-matrix least-squares techniques gave an R factor of 0.0785 for 4356 independent reflections. The structure contains two enantiomorphous molecules, Λ and Δ, which are related by an inversion center. Compound 1 exhibited 3.5-fold more potent cytotoxic activity against NALM-6 human leukemia cells than the mono(phenanthroline)oxovanadium(IV) complex (diaqua)(1,10-phenanthroline)sulfatooxovanadium(IV) ([VO(SO4)(Phen)(H2O)2], compound 2) (IC50 values: 0.97±0.10 μM versus 3.40±0.20 μM; P=0.0004). Methyl substitution in the phenanthroline ligand enhanced the anti-leukemic activity of the mono(phenanthroline)oxovanadium(IV) complex 4.4-fold (IC50 values: 0.78±0.10 μM, compound 4, versus 3.40±0.20 μM, compound 2; P=0.0003) and the anti-leukemic activity of the bis(phenanthroline)oxovanadium(IV) complex 5.7-fold (IC50 values: 0.17±0.02 μM, compound 3, versus 0.97±0.10 μM, compound 1; P=0.001). The leading oxovanadium compound bis(4,7-dimethyl-1,10-phenanthroline)sulfatooxovanadium(IV) ([VO(SO4)(Me2-Phen)2], compound 3) triggered the production of reactive oxygen species (ROS) in human leukemia cells, caused G1-arrest and inhibited clonogenic growth at nanomolar concentrations.
AB - In a systematic effort to identify and develop effective anticancer agents, four oxovanadium(IV) complexes with 1,10-phenanthroline (Phen) or 4,7-dimethyl-1,10-phenanthroline (Me2-Phen) as ligand(s) were synthesized and characterized. Among the four oxovanadium(IV) complexes synthesized, the crystal structure of the bis(phenanthroline)oxovanadium(IV) complex bis(1,10-phenanthroline)sulfatooxovanadium(IV) ([VO(SO4)(Phen)2], compound 1) has been determined. Compound 1 crystallized in the space group P21/n with unit cell parameters a=14.2125 (17) A, b=10.8628 (13) A, c=20.143 (2) A, α=90°, β=102.569 (2)°, γ=90°, V=3035.3 (6) A3, and Z=4. The refinement of compound 1 by full-matrix least-squares techniques gave an R factor of 0.0785 for 4356 independent reflections. The structure contains two enantiomorphous molecules, Λ and Δ, which are related by an inversion center. Compound 1 exhibited 3.5-fold more potent cytotoxic activity against NALM-6 human leukemia cells than the mono(phenanthroline)oxovanadium(IV) complex (diaqua)(1,10-phenanthroline)sulfatooxovanadium(IV) ([VO(SO4)(Phen)(H2O)2], compound 2) (IC50 values: 0.97±0.10 μM versus 3.40±0.20 μM; P=0.0004). Methyl substitution in the phenanthroline ligand enhanced the anti-leukemic activity of the mono(phenanthroline)oxovanadium(IV) complex 4.4-fold (IC50 values: 0.78±0.10 μM, compound 4, versus 3.40±0.20 μM, compound 2; P=0.0003) and the anti-leukemic activity of the bis(phenanthroline)oxovanadium(IV) complex 5.7-fold (IC50 values: 0.17±0.02 μM, compound 3, versus 0.97±0.10 μM, compound 1; P=0.001). The leading oxovanadium compound bis(4,7-dimethyl-1,10-phenanthroline)sulfatooxovanadium(IV) ([VO(SO4)(Me2-Phen)2], compound 3) triggered the production of reactive oxygen species (ROS) in human leukemia cells, caused G1-arrest and inhibited clonogenic growth at nanomolar concentrations.
KW - Anticancer activity
KW - Crystal structure
KW - Oxovanadium(IV) complexes
KW - Reactive oxygen species
UR - http://www.scopus.com/inward/record.url?scp=0034737512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034737512&partnerID=8YFLogxK
U2 - 10.1016/S0162-0134(00)00060-X
DO - 10.1016/S0162-0134(00)00060-X
M3 - Article
C2 - 10857913
AN - SCOPUS:0034737512
SN - 0162-0134
VL - 78
SP - 321
EP - 330
JO - Journal of Inorganic Biochemistry
JF - Journal of Inorganic Biochemistry
IS - 4
ER -